Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma

Hirobumi Suzuki, Yoshihiro Hirata, Nobumi Suzuki, Sozaburo Ihara, Kosuke Sakitani, Yuka Kobayashi, Hiroto Kinoshita, Yoku Hayakawa, Atsuo Yamada, Hirotsugu Watabe, Keisuke Tateishi, Tsuneo Ikenoue, Yutaka Yamaji, Kazuhiko Koike

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Small bowel adenocarcinoma (SBA) is a rare, aggressive malignancy with a poor prognosis, and the mechanisms of carcinogenesis in SBA remain unclear. Our aims were to investigate the molecular mechanisms underlying SBA and to identify treatments by establishing and characterizing an SBA cell line and performing anti-cancer drug screening. SIAC1 cells, established from jejunal SBA, showed epithelial characteristics and formed organoids in 3D culture. SIAC1 cells had a heterozygous β-catenin; deletion mutation, resulting in a stable β-catenin; protein with enhanced Wnt/β-catenin activity. SIAC1 cells lacked MLH1 and MSH6 expression, and target genes such as TGFBR2 and ACVR2 showed frameshift mutations. Among 10 clinical SBA samples, 2 (20%) had interstitial deletions in β-catenin, expression of mismatch repair protein was aberrant in 4 (40%), and heterozygous frameshift mutations of three target genes were found in all 10 samples. On screening assay using 140 compounds, eribulin significantly inhibited SIAC1 cell growth both in vitro and in vivo by inhibition of the Wnt/β-catenin pathway via enhanced degradation of β-catenin;. In conclusion, we established an SBA cell line with molecular characteristics similar to those of clinical SBA samples, including β-catenin; deletion and mismatch repair protein deficiency, that will be useful for SBA research. Eribulin might be a candidate for SBA treatment due to its inhibitory effect on Wnt/β-catenin signaling.

LanguageEnglish
Pages550-562
Number of pages13
JournalAmerican Journal of Pathology
Volume185
Issue number2
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Suzuki, Hirobumi ; Hirata, Yoshihiro ; Suzuki, Nobumi ; Ihara, Sozaburo ; Sakitani, Kosuke ; Kobayashi, Yuka ; Kinoshita, Hiroto ; Hayakawa, Yoku ; Yamada, Atsuo ; Watabe, Hirotsugu ; Tateishi, Keisuke ; Ikenoue, Tsuneo ; Yamaji, Yutaka ; Koike, Kazuhiko. / Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma. In: American Journal of Pathology. 2015 ; Vol. 185, No. 2. pp. 550-562.
@article{68b6848ca0f04ede824118d46c7cc52c,
title = "Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma",
abstract = "Small bowel adenocarcinoma (SBA) is a rare, aggressive malignancy with a poor prognosis, and the mechanisms of carcinogenesis in SBA remain unclear. Our aims were to investigate the molecular mechanisms underlying SBA and to identify treatments by establishing and characterizing an SBA cell line and performing anti-cancer drug screening. SIAC1 cells, established from jejunal SBA, showed epithelial characteristics and formed organoids in 3D culture. SIAC1 cells had a heterozygous β-catenin; deletion mutation, resulting in a stable β-catenin; protein with enhanced Wnt/β-catenin activity. SIAC1 cells lacked MLH1 and MSH6 expression, and target genes such as TGFBR2 and ACVR2 showed frameshift mutations. Among 10 clinical SBA samples, 2 (20{\%}) had interstitial deletions in β-catenin, expression of mismatch repair protein was aberrant in 4 (40{\%}), and heterozygous frameshift mutations of three target genes were found in all 10 samples. On screening assay using 140 compounds, eribulin significantly inhibited SIAC1 cell growth both in vitro and in vivo by inhibition of the Wnt/β-catenin pathway via enhanced degradation of β-catenin;. In conclusion, we established an SBA cell line with molecular characteristics similar to those of clinical SBA samples, including β-catenin; deletion and mismatch repair protein deficiency, that will be useful for SBA research. Eribulin might be a candidate for SBA treatment due to its inhibitory effect on Wnt/β-catenin signaling.",
author = "Hirobumi Suzuki and Yoshihiro Hirata and Nobumi Suzuki and Sozaburo Ihara and Kosuke Sakitani and Yuka Kobayashi and Hiroto Kinoshita and Yoku Hayakawa and Atsuo Yamada and Hirotsugu Watabe and Keisuke Tateishi and Tsuneo Ikenoue and Yutaka Yamaji and Kazuhiko Koike",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ajpath.2014.10.006",
language = "English",
volume = "185",
pages = "550--562",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

Suzuki, H, Hirata, Y, Suzuki, N, Ihara, S, Sakitani, K, Kobayashi, Y, Kinoshita, H, Hayakawa, Y, Yamada, A, Watabe, H, Tateishi, K, Ikenoue, T, Yamaji, Y & Koike, K 2015, 'Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma', American Journal of Pathology, vol. 185, no. 2, pp. 550-562. https://doi.org/10.1016/j.ajpath.2014.10.006

Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma. / Suzuki, Hirobumi; Hirata, Yoshihiro; Suzuki, Nobumi; Ihara, Sozaburo; Sakitani, Kosuke; Kobayashi, Yuka; Kinoshita, Hiroto; Hayakawa, Yoku; Yamada, Atsuo; Watabe, Hirotsugu; Tateishi, Keisuke; Ikenoue, Tsuneo; Yamaji, Yutaka; Koike, Kazuhiko.

In: American Journal of Pathology, Vol. 185, No. 2, 01.01.2015, p. 550-562.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma

AU - Suzuki, Hirobumi

AU - Hirata, Yoshihiro

AU - Suzuki, Nobumi

AU - Ihara, Sozaburo

AU - Sakitani, Kosuke

AU - Kobayashi, Yuka

AU - Kinoshita, Hiroto

AU - Hayakawa, Yoku

AU - Yamada, Atsuo

AU - Watabe, Hirotsugu

AU - Tateishi, Keisuke

AU - Ikenoue, Tsuneo

AU - Yamaji, Yutaka

AU - Koike, Kazuhiko

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Small bowel adenocarcinoma (SBA) is a rare, aggressive malignancy with a poor prognosis, and the mechanisms of carcinogenesis in SBA remain unclear. Our aims were to investigate the molecular mechanisms underlying SBA and to identify treatments by establishing and characterizing an SBA cell line and performing anti-cancer drug screening. SIAC1 cells, established from jejunal SBA, showed epithelial characteristics and formed organoids in 3D culture. SIAC1 cells had a heterozygous β-catenin; deletion mutation, resulting in a stable β-catenin; protein with enhanced Wnt/β-catenin activity. SIAC1 cells lacked MLH1 and MSH6 expression, and target genes such as TGFBR2 and ACVR2 showed frameshift mutations. Among 10 clinical SBA samples, 2 (20%) had interstitial deletions in β-catenin, expression of mismatch repair protein was aberrant in 4 (40%), and heterozygous frameshift mutations of three target genes were found in all 10 samples. On screening assay using 140 compounds, eribulin significantly inhibited SIAC1 cell growth both in vitro and in vivo by inhibition of the Wnt/β-catenin pathway via enhanced degradation of β-catenin;. In conclusion, we established an SBA cell line with molecular characteristics similar to those of clinical SBA samples, including β-catenin; deletion and mismatch repair protein deficiency, that will be useful for SBA research. Eribulin might be a candidate for SBA treatment due to its inhibitory effect on Wnt/β-catenin signaling.

AB - Small bowel adenocarcinoma (SBA) is a rare, aggressive malignancy with a poor prognosis, and the mechanisms of carcinogenesis in SBA remain unclear. Our aims were to investigate the molecular mechanisms underlying SBA and to identify treatments by establishing and characterizing an SBA cell line and performing anti-cancer drug screening. SIAC1 cells, established from jejunal SBA, showed epithelial characteristics and formed organoids in 3D culture. SIAC1 cells had a heterozygous β-catenin; deletion mutation, resulting in a stable β-catenin; protein with enhanced Wnt/β-catenin activity. SIAC1 cells lacked MLH1 and MSH6 expression, and target genes such as TGFBR2 and ACVR2 showed frameshift mutations. Among 10 clinical SBA samples, 2 (20%) had interstitial deletions in β-catenin, expression of mismatch repair protein was aberrant in 4 (40%), and heterozygous frameshift mutations of three target genes were found in all 10 samples. On screening assay using 140 compounds, eribulin significantly inhibited SIAC1 cell growth both in vitro and in vivo by inhibition of the Wnt/β-catenin pathway via enhanced degradation of β-catenin;. In conclusion, we established an SBA cell line with molecular characteristics similar to those of clinical SBA samples, including β-catenin; deletion and mismatch repair protein deficiency, that will be useful for SBA research. Eribulin might be a candidate for SBA treatment due to its inhibitory effect on Wnt/β-catenin signaling.

UR - http://www.scopus.com/inward/record.url?scp=84922334828&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2014.10.006

DO - 10.1016/j.ajpath.2014.10.006

M3 - Article

VL - 185

SP - 550

EP - 562

JO - American Journal of Pathology

T2 - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -